A serum test called T 50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T 50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T 50 at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T 50 was a significant covariate (P < .0001) for T 50 scores at 10 weeks and 1 year. In the total cohort, there was a highly significant (P < .0001) increase in T 50 of 26.6% after 10 weeks and T 50 remained stable after 1 year. T 50 change was inversely correlated to phosphate of −0.515 (P < .0001) and to change in serum albumin (P < .03). We found that T 50 increased from baseline to 10 weeks after transplantation with no further change after 1 year.
| INTRODUCTION
Chronic kidney disease (CKD) is associated with increased risk of cardiovascular complications and premature death compared to the general population. 1, 2 As recently reviewed, 3 such patients are prone to excessive vascular and tissue calcifications, and this is again highly correlated with cardiovascular morbidity and mortality. 4, 5 These complications accelerate with increasing stages of kidney disease, are most pronounced in patients receiving renal replacement therapy with dialysis, and are associated with a multifold increased risk of morbidity and mortality. 6, 7 Renal replacement therapy with kidney transplantation appears to yield lower rates of cardiovascular complications compared with persisting dialysis therapy, although still much higher than that of the general population. [8] [9] [10] The reasons for this discrepancy are not fully understood but the tendency to form accelerated tissue and vessel calcifications may have a role. [11] [12] [13] [14] Calcium metabolism is altered in several ways after successful kidney transplantation due to changes in renal and endocrine func- thereby accelerates vessel wall calcification. 15 Additionally, osteoprotegerin (OPG) and osteopontin (OPN) are both secreted locally from the vascular wall and by osteoblasts. 16 Recently, a novel in vitro test of serum that assesses overall calcification propensity of blood has been launched. 17 In a prospective, randomized, double blind and controlled study during the first year after kidney transplantation, ibandronate reduced bone turn-over, improved bone mineral density (BMD) in femur and in ultradistal radius, but had no significant effect on BMD in the lumbar spine compared with placebo. 23 Serum samples from this clinical trial were stored in a biobank and provided us with an ideal model for studying the calcification propensity score in more detail. In this study, the aim was to conduct secondary and post hoc analyses from the above-mentioned study on the evolution of T 50 during 1 year after transplantation, with a particular focus on the possible effect of ibandronate and on any biochemical variables with potential importance for the T 50 scores during this period.
| PATIENTS AND METHODS
Patient selection and details of treatment of the original patient cohort examined have been described in detail previously. 23 In short, The T 50 analysis in all samples was analyzed in one batch using laser detection of fully calcified particles as described by Pasch et al. 17 Adequate samples and T 50 results were obtained from all patients remaining in the trial, that is, from 129 patients at baseline, 127 patients at 10 weeks, and 123 patients at 1 year. The demographic data and relevant biochemical analyses for the patients included in the study are shown in Table 1 . All patients signed a statement that blood samples could be used for research purposes regarding outcomes of kidney transplantation, and the protocol was approved by the Regional
Committee for Medical Ethics in South/East Norway.
| Statistics
An ANCOVA model was used to check for differences between treatments in T 50 score at 10 and 52 weeks, using T 50 score at baseline as a covariate. Further analyses were performed using paired sample t test and multiple linear regression to model T 50 score at 10 weeks. Two sample t tests and Wilcoxon two sample tests were used to compare variables at baseline, 10 weeks, and 52 weeks (chi-square test was used for categorical data). Repeated-measures were not accounted for in any of the analyses.
| RESULTS
The study population consisted mainly of Caucasians with a mean age of 51 years, approximately 75% were males, and 88% participated in occasional or regular physical activity. Patients were included into the study after an average of 18.5 days post-transplantation, and this time-point thus represented study baseline. Further demographic and baseline data are presented in Table 1 . Formal statistical tests demonstrated that there were no significant differences between the groups in terms of any of the demographic, clinical, or biochemical variables at baseline (results not shown). Longitudinal biochemical data and T 50 scores for each of study groups and the cohort in total are presented in Table 2 .
Intervention with ibandronate caused no statistically significant differences to placebo in T 50 at 10 weeks (P = .0937) or at 1 year (P = .1163) as per ANCOVA analyses. Baseline T 50 was a significant covariate (P < .0001) in both ANCOVA models for T 50 scores at 10 weeks and 1 year.
Looking at the study cohort as a whole, a paired sample t-test
showed that there was a highly significant (P < .0001) early increase in T 50 of 26.6% from 186.5 ± 47.2 minutes at baseline to 236.1 ± 58.6 minutes after 10 weeks (Figure 1 ). From week 10 to 1 year, T 50 remained stable (−1.4% from week 10) at a high level (232.8 ± 62.9 minutes), maintaining a significant (P < .0001) mean change of 24.8% compared with baseline.
To further understand the T 50 scores in the first year after transplantation, and particularly the influence by other variables, multiple regression analyses were performed. Baseline T 50 score was included in all regression models with a significant effect on both T 50 at 10 weeks (P < .0001) and T 50 at 1 year (P < .0001). For all baseline biochemical variables tested, only calcium (P = .026) and phosphate (P = .006) had a predictive value for T 50 score at week 10.
There were similarly significant changes (P < .0001 for each variable, data not shown) in albumin, calcium, creatinine, hemoglobin, phosphate, and iPTH from baseline to week 10. Table 3 
| DISCUSSION
The present post hoc analyses share both insights into the evolution of calcification propensity over the first year after kidney transplantation and the modifying effects of bisphosphonate treatment over T A B L E 1 Demographics and baseline variables the same time period. The calcification propensity score showed a highly significant increase from baseline to 10 weeks with no further change up to 1 year after kidney transplantation, but there was no effect of ibandronate compared to placebo in any of the time-points.
A prolonged accelerated level of this score is potentially beneficial as it has recently been shown that higher T 50 at week 10 is associated with improved long-term cardiovascular outcomes in renal transplant patients. 19, 20 Our study is the first one in kidney transplant recipi- This study was originally designed to study the effect of ibandronate, a bisphosphonate, for prophylaxis against bone loss. 23 One could hypothesize that ibandronate and associated effects on bone turn-over, and its direct interactions with amorphous and crystalline calcium phosphate 22 might also have some impact on calcification propensity but this was apparently not the case, at best such an effect was marginal and short lasting. Recent reviews have expressed concern that the use of bisphosphonates may be contraindicated in patients with low GFR, and in those with low-turnover bone disease. 25 Our study of bisphosphonates administered for a year to such at-risk patients would possibly contribute to reducing this fear of worsening effects of bisphosphonates.
Furthermore, all our patients received additional calcium supplementation, and even if our study design did not allow us to separate any calcium effects from active vitamin D 3 or ibandronate, at least this additional and theoretically unwanted calcium did not seem to promote a tendency toward calcification as measured by serum calcification propensity.
This study was, however, not planned to detect meaningful differ- Further, the influence on the initial heavy immunosuppression on T 50 is not known. In our previous work, high prednisone doses and higher CNI trough levels were associated with lower T 50 values. 25 This association with CNI was also found in another cohort. 19 Whether this association is of causal or coincidental nature is, however, not known yet. Further work 26 suggests an association between T 50 and vascular changes in transplanted kidneys, which might be suggestive of "CNI toxicity," but only future studies can address any causality.
On the other hand, the strengths of our study include the prospective, randomized, and placebo-controlled design. The single-center approach has further assured a uniform approach to underlying treatment and procedures. Reasonable future work following this initial study would include further confirmation of the clinical usefulness of T 50 over longer term, of its ability to predict therapeutic effectiveness of any interventions, and addressing whether the changes in T 50 associate with the changes in bone mineral density.
In conclusion, we found that T 50 increased from baseline to 10 weeks after transplantation with no further change after 1 year.
Ibandronate had no effect on T 50 compared with placebo. The significantly improved calcification propensity measured with the T 50 score is encouraging in terms of utilizing this variable as a potential early biomarker for improved prognosis of cardiovascular mortality in the kidney transplant setting.
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